CARDIOGRAFIN Drug Patent Profile
✉ Email this page to a colleague
When do Cardiografin patents expire, and when can generic versions of Cardiografin launch?
Cardiografin is a drug marketed by Bracco and is included in one NDA.
The generic ingredient in CARDIOGRAFIN is diatrizoate meglumine. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the diatrizoate meglumine profile page.
Summary for CARDIOGRAFIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 32 |
Patent Applications: | 890 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CARDIOGRAFIN at DailyMed |
US Patents and Regulatory Information for CARDIOGRAFIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bracco | CARDIOGRAFIN | diatrizoate meglumine | INJECTABLE;INJECTION | 011620-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |